Equifax (EFX) Projected to Post Earnings on Tuesday - American Market News
π Equifax will release Q2 2026 earnings on Tuesday, July 21st, with analysts expecting $2.21 EPS and $1.6968 billion in revenue.
π The company previously beat Q1 estimates with $1.86 EPS and reported a 14.3% year-over-year revenue increase to $1.65 billion.
π° Equifax posted a return on equity of 20.41% and a net margin of 11.12% in the first quarter of fiscal 2026.
π Shares are currently priced at $172.62, trading below the 200-day moving average of $185.33.
π¦ Hedge funds and institutional investors own 96.20% of the company's outstanding stock.
π Ameriflex Group Inc. significantly increased its stake by 612.5% in the fourth quarter, now holding 114 shares.
π Bank of America lowered its price target from $250 to $225 while maintaining a buy rating.
π Mizuho cut its price objective from $222 to $210 but retained an outperform rating.
π CEO Mark W. Begor sold 37,791 shares in April under a pre-arranged Rule 10b5-1 trading plan.
π EVP Chad M. Borton sold 2,455 shares in May, reducing his direct ownership by 7.68%.
π The consensus analyst price target is $223.39 with a moderate buy rating from MarketBeat.
π’ Equifax operates as one of the three major consumer credit reporting agencies in the United States.
- Equifax reported Q1 revenue growth of 14.3% year-over-year, reaching $1.65 billion.
- The company achieved a return on equity of 20.41% and a net margin of 11.12% in the most recent quarter.
- Institutional ownership remains high at 96.20%, indicating strong investor confidence in the business model.
- Ameriflex Group Inc. increased its position by 612.5% in the fourth quarter, signaling institutional accumulation.
- Equifax stock is trading below its 200-day moving average of $185.33 at a price of $172.62.
- Multiple major analysts recently lowered their price targets, including Bank of America ($250 to $225) and Mizuho ($222 to $210).
- CEO Mark W. Begor sold 37,791 shares in April, representing a 12.21% decrease in his personal ownership stake.
- BNP Paribas Exane downgraded its target price to $185 and assigned a neutral rating on June 18th.